How targeting an epigenetic modifier is revolutionizing the fight against a challenging blood cancer
Imagine your body's instruction manual—your DNA—with annotations that determine which genes are read and which are silenced. This is the realm of epigenetics, a fascinating layer of biological control that doesn't change the DNA sequence itself but determines how it's interpreted. In cancer, these epigenetic annotations can be hijacked, creating harmful misprints that drive malignant growth. One such epigenetic culprit, a protein called EZH2, has emerged as a promising therapeutic target in multiple myeloma, a currently incurable blood cancer.
Multiple myeloma affects plasma cells—the white blood cells that normally produce antibodies to fight infection. When these cells turn malignant, they multiply uncontrollably in the bone marrow, crowding out healthy blood cells, causing bone destruction, and impairing kidney function. While treatments have improved dramatically over the past two decades, high-risk disease remains particularly challenging, with patients often experiencing rapid relapse and limited response to available therapies 1 .
Recent breakthroughs have illuminated how EZH2 contributes to myeloma progression and resistance—and more importantly, how inhibiting this epigenetic modifier may open new therapeutic avenues. This article explores the science behind EZH2 inhibition and how it's paving the way for a new class of myeloma treatments that effectively reprogram cancer cells.
EZH2 serves as a critical epigenetic regulator that becomes dysregulated in multiple myeloma, contributing to disease progression and treatment resistance.
Enhancer of Zeste Homolog 2 (EZH2) serves as the catalytic engine of the Polycomb Repressive Complex 2 (PRC2), a critical epigenetic regulator complex. Its primary function involves adding three methyl groups to a specific amino acid (lysine 27) on histone H3 proteins around which DNA is wrapped. This modification, known as H3K27me3, creates a "repression mark" that silences gene expression 1 .
Under normal circumstances, EZH2 plays vital roles in embryonic development, stem cell maintenance, and cell differentiation. However, in cancer, EZH2 becomes dysregulated—either overexpressed or mutated—leading to the inappropriate silencing of tumor suppressor genes that would normally restrain cell growth or trigger cell death 2 .
In multiple myeloma, EZH2 plays a multifaceted role in driving disease progression:
EZH2-mediated H3K27me3 deposition leads to the silencing of critical cell cycle regulators, particularly cyclin-dependent kinase inhibitors like p15 (CDKN2B) and p21 (CDKN1A). These proteins normally function as "brakes" on cell division. Their silencing allows myeloma cells to proliferate unchecked 1 .
A 2025 study revealed that EZH2 contributes directly to myeloma's devastating bone damage. Myeloma-associated adipocytes release cytokines (TNFα and IL-6) that activate EZH2 in myeloma cells. EZH2 then forms a complex with transcription factor AP2α to silence the tumor suppressor gene EMP1, leading to increased secretion of osteolytic cytokines that drive bone destruction 2 .
Emerging evidence indicates that EZH2 can promote cancer through mechanisms beyond its methyltransferase activity. A 2024 study demonstrated that EZH2 regulates the expression of SKP2—a protein critical for cell cycle progression—in a methyltransferase-independent manner. This discovery explains why simply inhibiting EZH2's enzymatic activity may not be sufficient to block all its oncogenic functions 4 .
| Term | Definition | Role in Myeloma |
|---|---|---|
| EZH2 | Histone methyltransferase; catalytic component of PRC2 | Frequently overexpressed; silences cell cycle control genes |
| H3K27me3 | Trimethylation of histone H3 at lysine 27 | Repressive mark that locks genes in silent state |
| Epigenetics | Heritable changes in gene expression without DNA sequence alteration | Allows cancer cells to change gene expression patterns |
| Tumor Suppressor Genes | Genes that protect cells from becoming cancerous | Inappropriately silenced by EZH2 in myeloma |
EZH2 inhibition represents a novel approach to cancer therapy by targeting the epigenetic reprogramming that drives malignancy.
The most well-established mechanism by which EZH2 inhibition fights myeloma involves the reactivation of silenced cell cycle regulators. When EZH2 is inhibited, the repressive H3K27me3 mark is removed from the promoters of genes encoding cyclin-dependent kinase inhibitors, particularly p15 and p21 1 .
These proteins then spring into action, applying brakes to the cell cycle machinery. The result is cell cycle arrest—myeloma cells become stuck, unable to progress through their division cycle. This arrest is followed by apoptosis (programmed cell death), effectively eliminating the malignant cells 1 .
A groundbreaking 2023 discovery revealed that EZH2 inhibition can overcome resistance to anti-CD38 monoclonal antibodies, a cornerstone of modern myeloma immunotherapy. Research demonstrated that EZH2 inhibition significantly upregulates CD38 expression on the surface of myeloma cells, making them more visible and vulnerable to antibody-based therapies like daratumumab and isatuximab .
This finding is particularly important for patients who develop resistance to these immunotherapies, often through downregulation of CD38. By re-expressing CD38, EZH2 inhibitors essentially restore the "target" that immunotherapies need to recognize and eliminate cancer cells .
The 2025 study on myeloma-induced bone destruction revealed that EZH2 inhibition can directly address the skeletal complications that profoundly impact patients' quality of life. By disrupting the EZH2-AP2α-EMP1 axis, EZH2 inhibitors reduce the production of bone-destroying cytokines, potentially preserving bone integrity and preventing fractures 2 .
This represents a dual therapeutic approach—not only directly attacking myeloma cells but also protecting the bone microenvironment that supports their growth.
Cell Cycle Arrest
Apoptosis
Bone Protection
Immunotherapy Enhancement
A pivotal study published in Blood Cancer Journal provided crucial evidence for EZH2 inhibition as a therapeutic strategy in myeloma.
The researchers employed a comprehensive strategy to validate EZH2 as a therapeutic target:
Analysis of gene expression data from nearly 1,500 myeloma patients to examine relationship between EZH2 expression and outcomes 1 .
Treatment of myeloma cell lines with small-molecule EZH2 inhibitors (GSK126 and EPZ005687) to assess effects on proliferation and apoptosis 1 .
Chromatin immunoprecipitation (ChIP) assays to examine changes in H3K27me3 levels at specific gene loci following EZH2 inhibition 1 .
| Experimental Approach | Key Finding | Clinical Implication |
|---|---|---|
| Survival Analysis | High EZH2 expression associated with significantly poorer overall survival | EZH2 expression may serve as a prognostic biomarker |
| Cell Viability Assays | EZH2 inhibition significantly reduced myeloma cell proliferation | Targeted EZH2 inhibition has direct anti-myeloma effects |
| Cell Cycle Analysis | Treatment induced G1 cell cycle arrest | Confirmed effect on cell cycle regulation |
| Apoptosis Assays | Cell cycle arrest was followed by programmed cell death | Demonstrated durable anti-cancer effect |
| Gene Expression | Upregulation of CDKN1A (p21) and CDKN2B (p15) | Identified key mediators of the therapeutic effect |
| Chromatin Immunoprecipitation | Loss of H3K27me3 mark at cell cycle regulator genes | Confirmed epigenetic mechanism of action |
Reduction in Cell Proliferation
Increase in p21 Expression
Cells in G1 Arrest
Reduction in H3K27me3
A growing arsenal of research tools allows scientists to precisely interrogate EZH2 function and inhibition.
| Research Tool | Function/Description | Application in Myeloma Research |
|---|---|---|
| GSK126 | Selective small-molecule EZH2 inhibitor | Reduces H3K27me3 levels; suppresses myeloma cell proliferation 3 |
| EPZ-6438 (Tazemetostat) | FDA-approved EZH2 inhibitor | Induces CD38 expression; enhances anti-CD38 immunotherapy |
| UNC1999 | Orally bioavailable EZH2 inhibitor | Used in combination therapy studies; demonstrates in vivo efficacy 8 |
| siRNA/shRNA EZH2 | Gene silencing tools | Demonstrates enzyme-independent EZH2 functions; reduces SKP2 expression 4 |
| H3K27me3-specific Antibodies | Detect trimethylated H3K27 | Measure EZH2 functional activity; monitor inhibitor efficacy 1 |
| 5-Azacytidine | DNA methyltransferase inhibitor | Used in combination with EZH2 inhibitors for enhanced epigenetic reprogramming 8 |
EZH2 inhibition shows promise particularly for high-risk myeloma and in combination with other therapeutic approaches.
The ability of EZH2 inhibition to target high-risk molecular features makes it particularly attractive. Patients with certain genetic abnormalities—such as t(4;14), t(14;16), or 17p deletion—continue to experience poor outcomes despite advances in myeloma therapy.
Since EZH2 overexpression is associated with these high-risk features, targeting EZH2 may specifically address this unmet clinical need 1 .
The future of EZH2 targeting likely lies in rational combinations:
As demonstrated, EZH2 inhibition can enhance the efficacy of anti-CD38 antibodies by increasing target expression .
Dual inhibition of EZH2 and G9a (a H3K9 methyltransferase) has shown enhanced anti-myeloma effects by activating interferon signaling and suppressing the IRF4-MYC axis 3 .
Combining EZH2 inhibition with DNMT inhibitors (like 5-azacytidine) creates extensive epigenomic reprogramming, activating apoptotic and cell cycle genes 8 .
Response Rate
Response Rate
Response Rate
Response Rate
EZH2 inhibition represents a paradigm shift in cancer treatment by targeting epigenetic misprogramming.
The investigation into EZH2 inhibition represents a paradigm shift in how we approach cancer treatment—by targeting the epigenetic misprogramming that drives malignancy rather than just attacking rapidly dividing cells. The compelling preclinical evidence supporting EZH2 inhibition in myeloma has paved the way for clinical trials that are currently evaluating this approach in patients.
As research advances, we're learning that EZH2's role in myeloma is even more complex than initially appreciated—with both enzyme-dependent and independent functions, and connections to bone health, immunotherapy response, and high-risk disease features. This complexity suggests that optimal therapeutic strategies may require combination approaches that address multiple aspects of EZH2 biology.
The journey of EZH2 from basic biological curiosity to promising therapeutic target exemplifies how decoding cancer's epigenetic language can translate into tangible benefits for patients.
While challenges remain—including optimizing patient selection, managing potential resistance, and identifying ideal combination partners—EZH2 inhibition represents a promising new chapter in the fight against multiple myeloma.
As this field advances, we move closer to a future where epigenetic therapies may help transform multiple myeloma from a devastating disease to a manageable condition, particularly for those patients with high-risk features who have traditionally had limited options.
Targeting specific epigenetic alterations in individual patients
Rational drug combinations to overcome resistance
Using molecular markers to select patients most likely to benefit